Variable | At 3 Months n = 249* (83 deaths) | At 6 Months n = 248* (102 deaths) | ||
---|---|---|---|---|
OR (95%CI) | p-value | OR (95%CI) | p-value | |
Patient Characteristics | ||||
 Gender Female (ref = male) | 1.12 (0.63–1.99) | 0.69 | 0.91 (0.52–1.59) | 0.75 |
 Age (per year) | 1.02 (1–1.04) | 0.13 | 1.01 (0.99–1.04) | 0.17 |
ECOG-PS (miss. = 10) |  | < 0.01 |  | < 0.01 |
 - 0–1 | 1.00 |  | 1.00 |  |
 - 2 | 1.83 (0.96–3.5) |  | 2.12 (1.15–3.9) |  |
 - 3–4 | 4.86 (2.38–9.95) |  | 5.07 (2.48–10.39) |  |
Charlson comorbidity index (per point) | 1.02 (1–1.03) | 0.80 | 0.94 (0.82–1.09) | 0.44 |
Cancer Characteristics | ||||
Type of cancer | ||||
 - Digestive (ref = absence) | 1.22 (0.69–2.14) | 0.50 | 1.05 (0.61–1.82) | 0.86 |
 - Thoracic (ref = absence) | 1.49 (0.83–2.67) | 0.19 | 1.9 (1.07–3.36) | 0.03 |
 - Head and Neck (ref = absence) | 0.42 (0.17–1.06) | 0.07 | 0.38 (0.16–0.92) | 0.03 |
 - Gynecological (ref = absence) | 1.13 (0.49–2.56) | 0.78 | 1.1 (0.5–2.45) | 0.81 |
 -Genito-urinary (ref = absence) | 1.0 (0.43–2.33) | 1 | 0.7 (0.3–1.63) | 0.41 |
 - Other (ref = absence) | 0.68 (0.26–1.80) | 0.44 | 0.93 (0.39–2.24) | 0.87 |
Metastatic disease (miss. = 12) (ref = absence) | 2.29 (1.33–4) | < 0.01 | 2.46 (1.45–4.16) | < 0.01 |
Previous anticancer treatment | ||||
 - Surgery (ref = absence) | 0.60 (0.35–1.02) | 0.06 | 0.60 (0.36–1) | 0.05 |
 - Radiotherapy (ref = absence) | 0.71 (0.4–1.27) | 0.25 | 0.86 (0.5–1.48) | 0.58 |
 - Chemotherapy (ref = absence) | 0.71 (0.42–1.21) | 0.20 | 1 (0.6–1.67) | 0.99 |
Cancer status (miss. = 6) |  | 0.19 |  | 0.03 |
 - Controlled or in remission for < 5 years | 1.00 |  | 1.00 |  |
 - Newly diagnosed / recurrence | 1.41 (0.73–2.69) |  | 1.65 (0.88–3.08) |  |
 - In progression | 1.92 (0.95–3.89) |  | 2.57 (1.29–5.11) |  |
ICU Characteristics | ||||
 Reason of ICU admission | ||||
  Tumor progression (ref = absence) | 2.67 (1.47–4.88) | < 0.01 | 2.72 (1.49–4-95) | < 0.01 |
  - Thrombotic event (ref = absence) | 1.66 (0.63–4.39) | 0.30 | 2.44 (0.91–6.54) | 0.08 |
  - Bleeding (ref = absence) | 1.13 (0.49–2.56) | 0.78 | 1.1 (0.5–2.45) | 0.81 |
  - Complications of anticancer treatment (ref = absence) | 0.84 (0.45–1.59) | 0.60 | 1.14 (0.63–2.06) | 0.67 |
  - Not related to cancer (ref = absence) | 0.53 (0.31–0.91) | 0.02 | 0.4 (0.24–0.68) | <.01 |
 SAPS II (per point) | 1.02 (1–1.03) | 0.03 | 1.02 (1.0–1.03) | 0.02 |
Supportive Care | ||||
 - Vasopressors (ref = absence) | 1.17 (0.68–2.03) | 0.57 | 1.04 (0.61–1.77) | 0.88 |
 - Invasive ventilation (ref = absence) | 0.8 (0.46–1.37) | 0.41 | 0.78 (0.47–1.31) | 0.35 |
 - Renal replacement therapy (ref = absence) | 0.93 (0.36–2.37) | 0.87 | 0.82 (0.33–2.03) | 0.66 |
TLD before ICU discharge (ref = absence) | 6.53 (3.11–13.74) | < 0.01 | 3.22 (1.25–8.29) | < 0.02 |
Length of stay in ICU (per day) | 0.99 (0.96–1.02) | 0.42 | 0.99 (0.96–1.01) | 0.30 |